Back to search
FDAFDA · Food and drugs·Recall number D-0222-2025

Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc., Greenville, SC 29605, NDC 0121-0775-16

Published February 12, 2025 · Recall initiated: January 7, 2025

Summary

FDA records drug Class III recall D-0222-2025, published February 12, 2025 and initiated January 7, 2025. Recalling firm: PAI Holdings, LLC. dba Pharmaceutical Associates Inc; Status: Terminated; Reported quantity: 4080 Bottles; Lot: Lot number 4B07, Exp Date: 2026-OCT-31. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent; sodium benzoate preservative

What to do

Voluntary: Firm initiated · Letter

Get an email if GUAIFENESIN AND CODEINE PHOSPHATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GUAIFENESIN AND CODEINE PHOSPHATE
Manufacturer
PAI Holdings, LLC. dba Pharmaceutical Associates Inc
Distributor
OH
Lot
Lot number 4B07, Exp Date: 2026-OCT-31
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical Associates, Inc., Greenville, SC 29605, NDC 0121-0775-16 recalled?

Yes. FDA published recall D-0222-2025 on February 12, 2025. Reported hazard: Superpotent; sodium benzoate preservative

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GUAIFENESIN AND CODEINE PHOSPHATE.